Patents by Inventor Marie-Ange Buyse
Marie-Ange Buyse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952418Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.Type: GrantFiled: February 12, 2020Date of Patent: April 9, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
-
Publication number: 20240067944Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.Type: ApplicationFiled: July 7, 2023Publication date: February 29, 2024Applicant: Novo Nordisk A/SInventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
-
Publication number: 20230416404Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.Type: ApplicationFiled: September 6, 2023Publication date: December 28, 2023Inventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
-
Patent number: 11787874Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.Type: GrantFiled: November 15, 2018Date of Patent: October 17, 2023Assignee: Novo Nordisk A/SInventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
-
Patent number: 11753465Abstract: The present invention relates to amino acid sequences that are directed against interleukin 23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODY® molecules against IL-23 and one NANOBODY® molecule against serum albumin, linked by two linkers. In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).Type: GrantFiled: March 1, 2021Date of Patent: September 12, 2023Assignees: Ablynx N.V., SanofiInventor: Marie-Ange Buyse
-
Publication number: 20230242620Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: April 13, 2023Publication date: August 3, 2023Applicants: Ablynx N.V., SanofiInventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 11708404Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: April 13, 2022Date of Patent: July 25, 2023Assignees: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20230203146Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: March 17, 2023Publication date: June 29, 2023Inventors: Rene Georg OTT, Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA, Pascal MERCHIERS, Frederik STEVENAERT
-
Patent number: 11649290Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: November 27, 2019Date of Patent: May 16, 2023Assignee: Merck Sharp & Dohme LLCInventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
-
Patent number: 11644471Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: GrantFiled: December 23, 2013Date of Patent: May 9, 2023Assignees: Ablynx N.V., SanofiInventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Publication number: 20220380445Abstract: The present invention relates to amino acid sequences binding to serum albumin. In particular, the present invention relates to improved immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”), and more in particular improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”) binding to serum albumin, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such improved serum albumin binders.Type: ApplicationFiled: April 19, 2022Publication date: December 1, 2022Applicant: Ablynx N. V.Inventor: Marie-Ange Buyse
-
Publication number: 20220362393Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.Type: ApplicationFiled: May 10, 2021Publication date: November 17, 2022Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
-
Patent number: 11485778Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: December 27, 2021Date of Patent: November 1, 2022Assignees: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11485777Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: March 29, 2021Date of Patent: November 1, 2022Assignees: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220332806Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: March 17, 2022Publication date: October 20, 2022Applicants: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220332807Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: March 25, 2022Publication date: October 20, 2022Applicants: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220324951Abstract: The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISV” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present.Type: ApplicationFiled: March 17, 2022Publication date: October 13, 2022Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11466089Abstract: The present invention relates to polypeptides directed against or specifically binding to C—X—C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2017Date of Patent: October 11, 2022Assignee: Ablynx N.V.Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Publication number: 20220298227Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: August 23, 2021Publication date: September 22, 2022Applicant: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Publication number: 20220289860Abstract: The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: ApplicationFiled: January 19, 2022Publication date: September 15, 2022Inventors: Marie-Ange Buyse, Guy Hermans, Sven Lindemann, Hans Guehring, Ralf Guenther, Roland Kellner